AdvaMed03.23.16
AdvaMed Accel – the division within the Advanced Medical Technology Association that addresses the needs and challenges of smaller medical technology manufacturers – has appointed Patrick Daly, president and CEO of Cohera Medical Inc., as chairman of the Accel Board of Directors for a two-year term.
Daly has served on the Accel Board since 2012 and has been an active member of AdvaMed’s Board of Directors since 2014, advocating on behalf of smaller manufacturers.
“Smaller and emerging medical technology companies are a cornerstone of the innovation ecosystem and the source of so many cutting-edge medical advances,” said Daly. “I know firsthand the challenges these companies face first to obtain the necessary funding to get their products off the drawing board and then to navigate the complex regulatory pathways at FDA and CMS. I am honored to be leading AdvaMed Accel, which is doing so much to help smaller companies get their innovative technologies to patients and physicians.”
As Accel chairman, Daly will work to enact policies that improve the efficiency and predictability of processes at both the Center for Medicare and Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA), in addition to other policies to encourage capital formation, including changes to the tax code and expansion and enhancement of public funding available for translational research.
“Accel will benefit immensely from Patrick’s experience and commitment to patient care,” said Ashley Wittorf, executive director and senior vice president of AdvaMed Accel. “From his years of leadership positions at Johnson & Johnson, he knows what it’s like to work for one of the world’s most successful multinationals. But he also brings the perspective of an entrepreneur who’s had to secure private funding and steer his products to market.”
Daly succeeds CVRx President and CEO Nadim Yared, who served as chair of the Accel board since 2014.
“Nadim has been a tireless advocate for Accel companies during his tenure as chair,” said Wittorf. “He has worked to increase the engagement of small companies in the association’s advocacy work – and bring companies of all sizes together – to improve the medtech innovation ecosystem. Under Nadim’s leadership, Accel companies have played an increasingly important role in AdvaMed’s outreach efforts to key stakeholders, including Capitol Hill, FDA, CMS and the investment community.”
AdvaMed Accel also appointed Intersect ENT President and CEO Lisa Earnhardt to the Accel board.
Daly has served on the Accel Board since 2012 and has been an active member of AdvaMed’s Board of Directors since 2014, advocating on behalf of smaller manufacturers.
“Smaller and emerging medical technology companies are a cornerstone of the innovation ecosystem and the source of so many cutting-edge medical advances,” said Daly. “I know firsthand the challenges these companies face first to obtain the necessary funding to get their products off the drawing board and then to navigate the complex regulatory pathways at FDA and CMS. I am honored to be leading AdvaMed Accel, which is doing so much to help smaller companies get their innovative technologies to patients and physicians.”
As Accel chairman, Daly will work to enact policies that improve the efficiency and predictability of processes at both the Center for Medicare and Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA), in addition to other policies to encourage capital formation, including changes to the tax code and expansion and enhancement of public funding available for translational research.
“Accel will benefit immensely from Patrick’s experience and commitment to patient care,” said Ashley Wittorf, executive director and senior vice president of AdvaMed Accel. “From his years of leadership positions at Johnson & Johnson, he knows what it’s like to work for one of the world’s most successful multinationals. But he also brings the perspective of an entrepreneur who’s had to secure private funding and steer his products to market.”
Daly succeeds CVRx President and CEO Nadim Yared, who served as chair of the Accel board since 2014.
“Nadim has been a tireless advocate for Accel companies during his tenure as chair,” said Wittorf. “He has worked to increase the engagement of small companies in the association’s advocacy work – and bring companies of all sizes together – to improve the medtech innovation ecosystem. Under Nadim’s leadership, Accel companies have played an increasingly important role in AdvaMed’s outreach efforts to key stakeholders, including Capitol Hill, FDA, CMS and the investment community.”
AdvaMed Accel also appointed Intersect ENT President and CEO Lisa Earnhardt to the Accel board.